Andre Horatscheck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andre Horatscheck has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Marc Nazaré
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Berlin, Germany
3 shared publications - Martin Neuenschwander
Marc Nazare ‐ Chemical Biology Leibniz Institute fur Molecular Pharmacologie Robert‐Roessle‐Strasse 10 13125 Berlin Germany
3 shared publications - Volker Haucke
Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany
3 shared publications - Adam McCluskey
Chemistry, School of Environmental and Life Science, The University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia
2 shared publications - Claire Le Manach
DMPK, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 43183, Sweden
2 shared publications Dale Taylor
Holistic Drug Discovery and Development (H3D) Centre
2 shared publications
Latest Publications
- 16 August 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (16)
Front Cover: Inhibition of the Clathrin Terminal Domain—Amphiphysin Protein–Protein Interaction. Probing the Pitstop 2 Aromatic Moiety (ChemMedChem 16/2025)
- 16 August 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (16)
Front Cover: Inhibition of the Clathrin Terminal Domain—Amphiphysin Protein–Protein Interaction. Probing the Pitstop 2 Aromatic Moiety (ChemMedChem 16/2025)
- Open Access
- 11 July 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (16) , e202500321
Inhibition of the Clathrin Terminal Domain—Amphiphysin Protein–Protein Interaction. Probing the Pitstop 2 Aromatic Moiety
Pitstop 2, (Z)‐N‐(5‐(4‐bromenzylidene)‐4‐oxo‐4,5‐dihydrothiazol‐2‐yl)naphthalene‐1‐sulfonamide (1) inhibits the clathrin terminal domain–amphiphysin interaction (NTD‐PPI) and has been widely used to investigate endocytosis. Herein, the synthesis of 56 novel Pitstop 2 analogues via four discrete focused libraries is reported. Specific modification to the 4‐bromonenzylidene moiety is explored, and their ability to inhibit the NTD‐PPI interaction is examined by ELISA. In cell endocytosis, effects are measured for selective analogues as is the inhibition of dynamin, another protein involved in the endocytosis process. The most NTD‐PPI active analogues retain 2‐ and 4‐disposed substituents on the aromatic head, with 2,3,4‐trihydroxy (28) the most active (IC50 0.94 μm). Catechol‐free 2,3‐dihydroxybenzo[b][1,4]dioxone (54) is a more promising lead with an NTD‐PPI IC50 = 1.16 μm. The corresponding benzo[d][1,3]dioxole (53) is threefold less active suggesting ring size preference at this position. Nine analogues show improved or comparable NTD‐PPI activity to Pitstop 2 with IC50 values from 0.94 to 2.1 μM. Heterocyclic analogues are well tolerated and potent inhibitors of CME in U2OS cells, in particular, benzofuran 67 (NTD‐PPI IC50 1.5 μm and CME IC50 6.8 ± 2.7 μm). This positions 67 as one of the most cell active inhibitors of clathrin‐mediated endocytosis yet reported.
- 11 July 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (16) , e202500321
Open AccessInhibition of the Clathrin Terminal Domain—Amphiphysin Protein–Protein Interaction. Probing the Pitstop 2 Aromatic Moiety
Pitstop 2, (Z)‐N‐(5‐(4‐bromenzylidene)‐4‐oxo‐4,5‐dihydrothiazol‐2‐yl)naphthalene‐1‐sulfonamide (1) inhibits the clathrin terminal domain–amphiphysin interaction (NTD‐PPI) and has been widely used to investigate endocytosis. Herein, the synthesis of 56 novel Pitstop 2 analogues via four discrete focused libraries is reported. Specific modification to the 4‐bromonenzylidene moiety is explored, and their ability to inhibit the NTD‐PPI interaction is examined by ELISA. In cell endocytosis, effects are measured for selective analogues as is the inhibition of dynamin, another protein involved in the endocytosis process. The most NTD‐PPI active analogues retain 2‐ and 4‐disposed substituents on the aromatic head, with 2,3,4‐trihydroxy (28) the most active (IC50 0.94 μm). Catechol‐free 2,3‐dihydroxybenzo[b][1,4]dioxone (54) is a more promising lead with an NTD‐PPI IC50 = 1.16 μm. The corresponding benzo[d][1,3]dioxole (53) is threefold less active suggesting ring size preference at this position. Nine analogues show improved or comparable NTD‐PPI activity to Pitstop 2 with IC50 values from 0.94 to 2.1 μM. Heterocyclic analogues are well tolerated and potent inhibitors of CME in U2OS cells, in particular, benzofuran 67 (NTD‐PPI IC50 1.5 μm and CME IC50 6.8 ± 2.7 μm). This positions 67 as one of the most cell active inhibitors of clathrin‐mediated endocytosis yet reported.
- Open Access
- 12 May 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (10) , 10156-10172
Cell-Based Progression of Spiroindoline Phenotypic Hits Leads to the Identification of Compounds with Diverging Parasitological Profiles against the Human Malaria Parasite Plasmodium falciparum
In the search for novel chemotypes with high sp3 character and activity against the human malaria parasite Plasmodium falciparum, a spiroindoline series was identified from a phenotypic high-throughput screening campaign. The spiroindoline hit 2 displayed good activity against both drug-sensitive and multidrug-resistant Plasmodium strains, making it an attractive starting point for hit-to-lead progression. Structure-activity relationship studies led to the identification of a novel pyridylspiroindoline frontrunner (50) with improved antiplasmodial activity, aqueous solubility, and microsomal metabolic stability. Data from additional parasitological profiling suggested that 50 likely has a mode of action differing from that of the original spiroindoline hit. Compound 50 showed excellent in vivo pharmacokinetics with efficacy being achieved in a humanized immunodeficient NSG mouse P. falciparum infection model. This provided a pharmacological proof-of-concept for this series, making it a valuable starting point for further optimization in the quest for novel antimalarial therapeutics.
- 12 May 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (10) , 10156-10172
Open AccessCell-Based Progression of Spiroindoline Phenotypic Hits Leads to the Identification of Compounds with Diverging Parasitological Profiles against the Human Malaria Parasite Plasmodium falciparum
In the search for novel chemotypes with high sp3 character and activity against the human malaria parasite Plasmodium falciparum, a spiroindoline series was identified from a phenotypic high-throughput screening campaign. The spiroindoline hit 2 displayed good activity against both drug-sensitive and multidrug-resistant Plasmodium strains, making it an attractive starting point for hit-to-lead progression. Structure-activity relationship studies led to the identification of a novel pyridylspiroindoline frontrunner (50) with improved antiplasmodial activity, aqueous solubility, and microsomal metabolic stability. Data from additional parasitological profiling suggested that 50 likely has a mode of action differing from that of the original spiroindoline hit. Compound 50 showed excellent in vivo pharmacokinetics with efficacy being achieved in a humanized immunodeficient NSG mouse P. falciparum infection model. This provided a pharmacological proof-of-concept for this series, making it a valuable starting point for further optimization in the quest for novel antimalarial therapeutics.
- Open Access
- 15 September 2022
- Published by Springer Nature in Nature Chemical Biology
- Vol. 19 (1) , 18-27
Development of selective inhibitors of phosphatidylinositol 3-kinase C2α
Phosphatidylinositol 3-kinase type 2α (PI3KC2α) and related class II PI3K isoforms are of increasing biomedical interest because of their crucial roles in endocytic membrane dynamics, cell division and signaling, angiogenesis, and platelet morphology and function. Herein we report the development and characterization of PhosphatidylInositol Three-kinase Class twO INhibitors (PITCOINs), potent and highly selective small-molecule inhibitors of PI3KC2α catalytic activity. PITCOIN compounds exhibit strong selectivity toward PI3KC2α due to their unique mode of interaction with the ATP-binding site of the enzyme. We demonstrate that acute inhibition of PI3KC2α-mediated synthesis of phosphatidylinositol 3-phosphates by PITCOINs impairs endocytic membrane dynamics and membrane remodeling during platelet-dependent thrombus formation. PITCOINs are potent and selective cell-permeable inhibitors of PI3KC2α function with potential biomedical applications ranging from thrombosis to diabetes and cancer.
- 15 September 2022
- Published by Springer Nature in Nature Chemical Biology
- Vol. 19 (1) , 18-27
Open AccessDevelopment of selective inhibitors of phosphatidylinositol 3-kinase C2α
Phosphatidylinositol 3-kinase type 2α (PI3KC2α) and related class II PI3K isoforms are of increasing biomedical interest because of their crucial roles in endocytic membrane dynamics, cell division and signaling, angiogenesis, and platelet morphology and function. Herein we report the development and characterization of PhosphatidylInositol Three-kinase Class twO INhibitors (PITCOINs), potent and highly selective small-molecule inhibitors of PI3KC2α catalytic activity. PITCOIN compounds exhibit strong selectivity toward PI3KC2α due to their unique mode of interaction with the ATP-binding site of the enzyme. We demonstrate that acute inhibition of PI3KC2α-mediated synthesis of phosphatidylinositol 3-phosphates by PITCOINs impairs endocytic membrane dynamics and membrane remodeling during platelet-dependent thrombus formation. PITCOINs are potent and selective cell-permeable inhibitors of PI3KC2α function with potential biomedical applications ranging from thrombosis to diabetes and cancer.
- Open Access
- 11 January 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box
Chemical matter is needed to target the divergent biology associated with the different life cycle stages of Plasmodium. Here, we report the parallel de novo screening of the Medicines for Malaria Venture (MMV) Pandemic Response Box against Plasmodium asexual and liver stage parasites, stage IV/V gametocytes, gametes, oocysts and as endectocides. Unique chemotypes were identified with both multistage activity or stage-specific activity, including structurally diverse gametocyte-targeted compounds with potent transmission-blocking activity, such as the JmjC inhibitor ML324 and the antitubercular clinical candidate SQ109. Mechanistic investigations prove that ML324 prevents histone demethylation, resulting in aberrant gene expression and death in gametocytes. Moreover, the selection of parasites resistant to SQ109 implicates the druggable V-type H+-ATPase for the reduced sensitivity. Our data therefore provides an expansive dataset of compounds that could be redirected for antimalarial development and also point towards proteins that can be targeted in multiple parasite life cycle stages.
- 11 January 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Open AccessMultistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box
Chemical matter is needed to target the divergent biology associated with the different life cycle stages of Plasmodium. Here, we report the parallel de novo screening of the Medicines for Malaria Venture (MMV) Pandemic Response Box against Plasmodium asexual and liver stage parasites, stage IV/V gametocytes, gametes, oocysts and as endectocides. Unique chemotypes were identified with both multistage activity or stage-specific activity, including structurally diverse gametocyte-targeted compounds with potent transmission-blocking activity, such as the JmjC inhibitor ML324 and the antitubercular clinical candidate SQ109. Mechanistic investigations prove that ML324 prevents histone demethylation, resulting in aberrant gene expression and death in gametocytes. Moreover, the selection of parasites resistant to SQ109 implicates the druggable V-type H+-ATPase for the reduced sensitivity. Our data therefore provides an expansive dataset of compounds that could be redirected for antimalarial development and also point towards proteins that can be targeted in multiple parasite life cycle stages.